|
|
Blood, 15 February 2007, Vol. 109, No. 4, pp. 1692-1700.
Prepublished online as a Blood First Edition Paper on October 5, 2006; DOI 10.1182/blood-2006-07-037077.
 Previous Article | Table of Contents | Next Article 
NEOPLASIA
Gene-expression signature of benign monoclonal gammopathy evident in multiple myeloma is linked to good prognosis
Fenghuang Zhan1,
Bart Barlogie1,
Varant Arzoumanian1,
Yongsheng Huang1,
David R. Williams1,
Klaus Hollmig1,
Mauricio Pineda-Roman1,
Guido Tricot1,
Frits van Rhee1,
Maurizio Zangari1,
Madhav Dhodapkar2, and
John D. Shaughnessy, Jr1
1 Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics, Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock;
2 Laboratory of Tumor Immunology and Immunotherapy, Rockefeller University, New York, NY
Monoclonal gammopathy of undetermined significance (MGUS) can progress to multiple myeloma (MM). Although these diseases share many of the same genetic features, it is still unclear whether global gene-expression profiling might identify prior genomic signatures that distinguish them. Through significance analysis of microarrays, 52 genes involved in important pathways related to cancer were differentially expressed in the plasma cells of healthy subjects (normal plasma-cell [NPC]; n = 22) and patients with stringently defined MGUS/smoldering MM (n = 24) and symptomatic MM (n = 351) (P < .001). Unsupervised hierarchical clustering of 351 patients with MM, 44 with MGUS (24 + 20), and 16 with MM from MGUS created 2 major cluster branches, one containing 82% of the MGUS patients and the other containing 28% of the MM patients, termed MGUS-like MM (MGUS-L MM). Using the same clustering approach on an independent cohort of 214 patients with MM, 27% were found to be MGUS-L. This molecular signature, despite its association with a lower incidence of complete remission (P = .006), was associated with low-risk clinical and molecular features and superior survival (P < .01). The MGUS-L signature was also seen in plasma cells from 15 of 20 patients surviving more than 10 years after autotransplantation. These data provide insight into the molecular mechanisms of plasma-cell dyscrasias.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
S. Blotta, P. Tassone, R. H. Prabhala, P. Tagliaferri, D. Cervi, S. Amin, J. Jakubikova, Y.-T. Tai, K. Podar, C. S. Mitsiades, et al.
Identification of novel antigens with induced immune response in monoclonal gammopathy of undetermined significance
Blood,
October 8, 2009;
114(15):
3276 - 3284.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J.-L. Harousseau, M. Attal, and H. Avet-Loiseau
The role of complete response in multiple myeloma
Blood,
October 8, 2009;
114(15):
3139 - 3146.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Anguiano, S. A. Tuchman, C. Acharya, K. Salter, C. Gasparetto, F. Zhan, M. Dhodapkar, J. Nevins, B. Barlogie, J. D. Shaughnessy Jr, et al.
Gene Expression Profiles of Tumor Biology Provide a Novel Approach to Prognosis and May Guide the Selection of Therapeutic Targets in Multiple Myeloma
J. Clin. Oncol.,
September 1, 2009;
27(25):
4197 - 4203.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Hoering, J. Crowley, J. D Shaughnessy Jr, K. Hollmig, Y. Alsayed, J. Szymonifka, S. Waheed, B. Nair, F. van Rhee, E. Anaissie, et al.
Complete remission in multiple myeloma examined as time-dependent variable in terms of both onset and duration in Total Therapy protocols
Blood,
August 13, 2009;
114(7):
1299 - 1305.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Fan, Y. Fan, N. Gupta, I. Matsuura, F. Liu, X. Z. Zhou, K. P. Lu, and C. Gelinas
Peptidyl-Prolyl Isomerase Pin1 Markedly Enhances the Oncogenic Activity of the Rel Proteins in the Nuclear Factor-{kappa}B Family
Cancer Res.,
June 1, 2009;
69(11):
4589 - 4597.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
O. Landgren, R. A. Kyle, R. M. Pfeiffer, J. A. Katzmann, N. E. Caporaso, R. B. Hayes, A. Dispenzieri, S. Kumar, R. J. Clark, D. Baris, et al.
Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study
Blood,
May 28, 2009;
113(22):
5412 - 5417.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. M. Weiss, J. Abadie, P. Verma, R. S. Howard, and W. M. Kuehl
A monoclonal gammopathy precedes multiple myeloma in most patients
Blood,
May 28, 2009;
113(22):
5418 - 5422.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. Xiong, X. Wu, S. Starnes, S. K. Johnson, J. Haessler, S. Wang, L. Chen, B. Barlogie, J. D. Shaughnessy Jr, and F. Zhan
An analysis of the clinical and biologic significance of TP53 loss and the identification of potential novel transcriptional targets of TP53 in multiple myeloma
Blood,
November 15, 2008;
112(10):
4235 - 4246.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Y. Kristinsson, T. R. Fears, G. Gridley, I. Turesson, U.-H. Mellqvist, M. Bjorkholm, and O. Landgren
Deep vein thrombosis after monoclonal gammopathy of undetermined significance and multiple myeloma
Blood,
November 1, 2008;
112(9):
3582 - 3586.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. Barlogie, M. Pineda-Roman, F. van Rhee, J. Haessler, E. Anaissie, K. Hollmig, Y. Alsayed, S. Waheed, N. Petty, J. Epstein, et al.
Thalidomide arm of Total Therapy 2 improves complete remission duration and survival in myeloma patients with metaphase cytogenetic abnormalities
Blood,
October 15, 2008;
112(8):
3115 - 3121.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. Barlogie, F. van Rhee, J. D. Shaughnessy Jr, J. Epstein, S. Yaccoby, M. Pineda-Roman, K. Hollmig, Y. Alsayed, A. Hoering, J. Szymonifka, et al.
Seven-year median time to progression with thalidomide for smoldering myeloma: partial response identifies subset requiring earlier salvage therapy for symptomatic disease
Blood,
October 15, 2008;
112(8):
3122 - 3125.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Dib, A. Gabrea, O. K. Glebov, P. L. Bergsagel, and W. M. Kuehl
Characterization of MYC Translocations in Multiple Myeloma Cell Lines
J Natl Cancer Inst Monographs,
July 1, 2008;
2008(39):
25 - 31.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
O. Landgren, L. R. Goldin, N. E. Caporaso, R. A. Kyle, and S. V. Rajkumar
Genetic Predisposition for Monoclonal Gammopathy of Undetermined Significance-reply-I
Mayo Clin. Proc.,
May 1, 2008;
83(5):
602 - 603.
[Full Text]
[PDF]
|
|
|
|
|
|
|
U.-M. Fagerli, R. U. Holt, T. Holien, T. K. Vaatsveen, F. Zhan, K. W. Egeberg, B. Barlogie, A. Waage, H. Aarset, H. Y. Dai, et al.
Overexpression and involvement in migration by the metastasis-associated phosphatase PRL-3 in human myeloma cells
Blood,
January 15, 2008;
111(2):
806 - 815.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Haessler, J. D. Shaughnessy Jr., F. Zhan, J. Crowley, J. Epstein, F. van Rhee, E. Anaissie, M. Pineda-Roman, M. Zangari, K. Hollmig, et al.
Benefit of Complete Response in Multiple Myeloma Limited to High-Risk Subgroup Identified by Gene Expression Profiling
Clin. Cancer Res.,
December 1, 2007;
13(23):
7073 - 7079.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Greipp
Progression risk for MGUS and SMM
Blood,
October 1, 2007;
110(7):
2226 - 2226.
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. K. Prasad, F. Zhan, J. Shaughnessy, D. Focosi, A. T. Andrews, R. A. Kyle, and S. V. Rajkumar
Smoldering Multiple Myeloma
N. Engl. J. Med.,
September 6, 2007;
357(10):
1048 - 1050.
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. van Rhee, V. Bolejack, K. Hollmig, M. Pineda-Roman, E. Anaissie, J. Epstein, J. D. Shaughnessy Jr, M. Zangari, G. Tricot, A. Mohiuddin, et al.
High serum-free light chain levels and their rapid reduction in response to therapy define an aggressive multiple myeloma subtype with poor prognosis
Blood,
August 1, 2007;
110(3):
827 - 832.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
